GeneDx appoints Bryan Dechairo as COO with $450K salary and $2.7M RSU award

GeneDx Holdings Corp.

Bryan Dechairo appointed COO effective Jan 2, 2025; reports to CEO Katherine Stueland.
Total annual base salary of $450,000 plus target annual bonus of 50% of base salary.
RSUs with $2.7M grant-date value vesting over 4 years; sign-on bonuses of $75K each in 2025 and 2026.
Dechairo previously CEO of Sherlock Biosciences; will oversee Product & Technology, Operations, Medical Affairs, Innovation.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bryan Dechairo

Chief Operating Officer

WGS · GeneDx Holdings Corp.

Effective: 2025-01-02
Filed: January 2, 2025, 6:59 PM ET

On January 2, 2025, GeneDx Holdings Corp. (the “Company”) announced the appointment of Bryan Dechairo, Ph.D., age 52, in the newly created role of Chief Operating Officer, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Bryan Dechairo was appointed as Chief Operating Officer at GeneDx Holdings Corp..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On January 2, 2025, GeneDx Holdings Corp. (the “Company”) announced the appointment of Bryan Dechairo, Ph.D., age 52, in the newly created role of Chief Operating Officer, effective immediately.

View on SEC.gov

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-25-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.